Clinical Trials
Gadopentetate dimeglumine has been evaluated across Phase 1 through Phase 4 and observational clinical trials sponsored by academic, federal, and pharmaceutical organizations. Encompassing completed, active, and terminated protocols, these studies investigate diagnostic magnetic resonance imaging in structural and vascular pathologies such as pancreatic adenocarcinoma, brain neoplasms, renal artery stenosis, and liver fibrosis. Overall, this body of research underscores the agent's established utility in evaluating oncological, renal, and cardiovascular diseases.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT00375830 | COMPLETED | Cancer |
Stanford University |
2006-01 | PHASE2 |
| NCT02371798 | WITHDRAWN | Meniere Disease |
Emory University |
2015-02 | |
| NCT02967380 | TERMINATED | Adult Anaplastic (Malignant) Meningioma; Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Choroid Plexus Neoplasm; Adult Diffuse Astrocytoma; Adult Ependymoblastoma; Adult Ependymoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Grade II Meningioma; Adult Medulloblastoma; Adult Mixed Glioma; Adult Oligodendroglioma; Adult Papillary Meningioma; Adult Pineal Gland Astrocytoma; Adult Pineoblastoma; Adult Primary Melanocytic Lesion of Meninges; Adult Supratentorial Primitive Neuroectodermal Tumor; Malignant Adult Intracranial Hemangiopericytoma; Metastatic Malignant Neoplasm in the Brain; Multiple Sclerosis; Recurrent Adult Brain Neoplasm |
University of Southern California |
2011-12-14 | |
| NCT02175069 | COMPLETED | Disorder of Shoulder |
Paracelsus Medical University |
2013-12 | PHASE4 |
| NCT02080312 | COMPLETED | Meniere's Disease |
University of California, San Diego |
2012-01 | |
| NCT02775786 | Active not recruiting | Pancreatic Adenocarcinoma |
Columbia University |
2013-11 | Not Applicable |
| NCT01416740 | WITHDRAWN | Shoulder Pain |
Milton S. Hershey Medical Center |
2009-12 | |
| NCT01260636 | COMPLETED | Carotid, Aortic, Renal or Peripheral Artery Disease |
Bracco Diagnostics, Inc |
2009-09 | PHASE3 |
| NCT01211873 | COMPLETED | Diagnostic Self Evaluation; Central Nervous System Diseases |
Guerbet |
2010-09 | PHASE3 |
| NCT00060008 | TERMINATED | Neurofibromatosis Type 1; Precancerous Condition |
Children's Hospital of Philadelphia |
2002-04 | |
| NCT01050829 | COMPLETED | Magnetic Resonance Imaging |
Bayer |
2010-01 | PHASE3 |
| NCT00937391 | COMPLETED | Magnetic Resonance Imaging |
Bayer |
2010-01 | PHASE3 |
| NCT00373152 | WITHDRAWN | Breast Cancer |
Masonic Cancer Center, University of Minnesota |
2005-03 | PHASE2 |
| NCT00999258 | Unknown status | Glomerular Filtration Rate|Chronic Allograft Nephropathy |
Temple University|Wyeth is now a wholly owned subsidiary of Pfizer |
2009-09 | Phase 4 |
| NCT00880061 | Terminated | Brain Neoplasm|Glioma |
National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) |
2009-04-07 | Phase 1 |
| NCT00019604 | TERMINATED | Liver Cancer; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
National Institutes of Health Clinical Center (CC) |
1998-08 | PHASE2 |
| NCT00043017 | COMPLETED | Breast Cancer |
American College of Radiology Imaging Network |
2002-05 | PHASE2 |
| NCT00652418 | COMPLETED | Magnetic Resonance Angiography; Peripheral Vascular Diseases; Peripheral Arterial Diseases |
Bayer |
2004-07 | PHASE2 |
| NCT00004936 | COMPLETED | Cervical Cancer |
American College of Radiology Imaging Network |
2000-04 | |
| NCT00005790 | WITHDRAWN | Brain and Central Nervous System Tumors |
Northwestern University |
1996-04 | |
| NCT00310557 | COMPLETED | Renal Artery Stenosis |
Bayer |
2003-12 | PHASE3 |
| NCT00310544 | COMPLETED | Myocardial Infarction |
Bayer |
2006-03 | PHASE2 |
| NCT00310609 | COMPLETED | Cardiovascular Abnormalities |
Bayer |
2003-12 | PHASE3 |
| NCT00309075 | COMPLETED | Stenosis |
Bayer |
2003-12 | PHASE3 |
| NCT00310596 | COMPLETED | Healthy |
Bayer |
2004-01 | PHASE1 |
| NCT00185276 | COMPLETED | Peripheral Vascular Disease |
Bayer |
2003-03 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2023-12-12)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
- Gadopentetate Dimeglumine Solubility in DMSO
- Gadopentetate Dimeglumine Stock Solution
- Gadopentetate Dimeglumine Storage
- Gadopentetate Dimeglumine Stability
- Gadopentetate Dimeglumine Molecular Weight
- Gadopentetate Dimeglumine SMILES
- Gadopentetate Dimeglumine CAS Number
- Gadopentetate Dimeglumine Chemical Structure (2D and 3D)
- Gadopentetate Dimeglumine SDS|MSDS